• Perimeter Medical Imaging AI launched its Claire surgical imaging device commercially, with first placements in the second quarter of 2026.
• Claire received FDA premarket approval in March 2026 as the first AI-enabled imaging device for breast cancer surgery.
• A multicenter randomized trial showed a statistically significant reduction in residual cancer compared with standard care alone.
• The hardware placement model targets approximately 70% gross margin through recurring revenue streams.
• Initial commercialization targets an estimated $650 million U.S. breast cancer market, with potential expansion into other surgical oncology applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perimeter Medical Imaging AI Inc. published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.